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Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically
different from nodular fasciitis and lack USP6, ROS1 and ETV6 gene rearrangements
Aims: Pseudosarcomatous myofibroblastic prolifera-
tions of the genitourinary tract have a debatable rela-
tionship with inflammatory myofibroblastic tumour
(generally lacking ALK rearrangement); however, they
share several overlapping features with nodular fasciitis
of soft tissue. As rearrangement of the USP6 gene has
been recently recognised as a recurrent alteration in
soft tissue nodular fasciitis, and several other alternative
gene fusions have been recently recognised in inflam-
matory myofibroblastic tumour, the aim of this study
was to investigate whether USP6, ROS1 or ETV6 rear-
rangements were present in these lesions (12 cases).
Methods and results: Fluorescence in-situ hybridisa-
tion analysis was performed by the use of bacterial
artificial chromosome-derived break-apart probes
against USP6, ROS1, and ETV6. Two cases with ade-
quate genetic material from recent paraffin tissue
blocks were also tested by use of a solid tumour gene
fusion detection assay via next-generation sequenc-
ing, targeting >50 known genes involved in recurrent
fusions. None of the genitourinary pseudosarcoma-
tous myofibroblastic proliferations was found to har-
bour USP6 (0/12), ROS1 (0/8) or ETV6 (0/7)
rearrangements, and no gene fusions were detected
in two cases studied by sequencing.
Conclusions: Despite overlap in histological and
immunohistochemical features between pseudosarco-
matous myofibroblastic proliferation and nodular
fasciitis, these tumours lack the recently recognised
USP6 rearrangements that occur in nodular fasciitis,
as well as alternative fusions found in ALK-negative
inflammatory myofibroblastic tumours. At present,
this diagnosis remains based primarily on clinical,
histological and immunohistochemical features.
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Introduction
Pseudosarcomatous myofibroblastic tumours of the
genitourinary tract,1 whether procedure-related or
spontaneous, can pose diagnostic challenges for
pathologists, owing to one or more worrying features,
such as high mitotic rate, an infiltrative growth pat-
tern, recurrence, and overlapping morphological and
immunophenotypic features with other spindle cell
tumours, such as low-grade leiomyosarcoma and sar-
comatoid carcinoma. These tumours are also known
by a variety of names, including fibromyxoid pseudo-
tumour and postoperative spindle cell nodule, and it
remains controversial whether this and inflammatory
myofibroblastic tumour2,3 are the same entity or dif-
ferent entities.4–7 Regardless of the terminology used,
both pseudosarcomatous myofibroblastic prolifera-
tions and inflammatory myofibroblastic tumours of
the urinary tract generally show non-aggressive
behaviour without metastasis, although some cases
have persisted or recurred, requiring multiple surgical
procedures. Therefore, recognition is important, as
the differential diagnosis for spindle cell tumours of
the urinary tract should almost always include con-
sideration of sarcomatoid carcinoma and sarcoma,
including leiomyosarcoma.
As rearrangement of the ubiquitin-specific protease
6 (USP6) gene has been recently recognised as a
recurrent alteration in soft tissue nodular fasciitis,8
and as pseudosarcomatous myofibroblastic prolifera-
tion of the genitourinary tract has a number of simi-
larities with nodular fasciitis, including labelling for
myofibroblastic marker smooth muscle actin, we
aimed to evaluate USP6 rearrangement in pseudosar-
comatous myofibroblastic tumours of the urinary
tract, in order to determine whether this may be a
confirmatory diagnostic test for this uncommon diag-
nosis, making it the genitourinary tract equivalent of
nodular fasciitis. Additionally, we also studied ROS1
and ETV6 for rearrangement, as these have been
recently implicated in a subset of ALK rearrange-
ment-negative inflammatory myofibroblastic
tumours.9,10 Two representative cases with the most
optimal genetic material were also tested with a gene
fusion detection panel targeting >50 genes involved
in recurrent gene fusions, by the use of next-genera-
tion sequencing.
Materials and methods
After obtaining institutional review board approval
from the Henry Ford Health System, we retrieved 17
cases of pseudosarcomatous myofibroblastic
proliferation of the genitourinary tract from our
pathology databases from 2002 to 2017, none of
which was included in a prior study of inflammatory
myofibroblastic tumours.11 Of the 17 cases, four were
reclassified upon histological review. One occurred in
the inguinal canal; as this is a non-visceral location,
this case was excluded. We studied the remaining 12
cases of pseudosarcomatous myofibroblastic prolifera-
tion, 10 of which occurred in the urinary bladder
and two in the renal pelvis. Histopathology and
immunohistochemical staining results were reviewed
by two of the authors (J.A.S.J. and S.R.W.). We
included pseudosarcomatous myofibroblastic prolifera-
tions with the following histological and immunohis-
tochemical features. Lesions were required to be
composed of spindle-shaped cells arranged in compact
fascicles or with a loose tissue culture-like appear-
ance. The spindle-shaped cells were required to be
bipolar with eosinophilic cytoplasm, and uniform
ovoid or spindle-shaped nuclei with smooth nuclear
contours. Stromal changes included myxoid change,
areas of collagenisation, haemorrhage, and scattered
inflammatory cells. As is the diagnosis of nodular
fasciitis, a specific cut-off of mitotic activity was not
employed; however, an absence of overt cytological
atypia, atypical mitosis, and necrosis was required.
The expected immunohistochemical phenotype
included positivity for smooth muscle actin or mus-
cle-specific actin, and negativity for p63, GATA3, and
high molecular weight cytokeratin. Variable staining
for desmin and broad-spectrum cytokeratin was
allowed, in light of previous reports showing these
findings.12,13 If not already performed at the time of
original diagnosis, ALK immunohistochemical stain-
ing was performed with anti-ALK antibody (mono-
clonal mouse anti-human CD246, ALK protein, clone
ALK-1; Dako, Carpinteria, CA, USA). As ALK rear-
rangement is rare in cases with negative immunohis-
tochemical staining,1,11,14 we did not perform ALK
fluorescence in-situ hybridisation (FISH).
F I S H
FISH analyses for USP6, ROS1 and ETV6 were per-
formed with bacterial artificial chromosome-derived
break-apart probes. FISH for USP6 was validated to
be positive in four well-characterised cases of nodular
fasciitis (Figure 1A,B) and one aneurysmal bone cyst,
and negative in eight histological mimics of nodular
fasciitis. ROS1 and ETV6 FISH was performed on all
12 cases, but lacked adequate hybridisation signals in
five cases each for ROS1 and ETV6, even after
repeated hybridisation. One case that was non-
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informative for ROS1 by FISH was informative by the
next-generation sequencing assay, bringing the totals
of ROS1 and ETV6 cases analysed to eight of 12 and
seven of 12, respectively.
N E X T - G E N E R A T I O N S E Q U E N C I N G
A multiplex RNA fusion panel (Archer FusionPlex
Solid Tumour Kit, ArcherDX, Inc, Boulder, CO, USA)
was applied to RNA extracted from representative for-
malin-fixed paraffin-embedded tissue tumour blocks of
two of the most recent cases regarded as having the
most adequate genetic material for assessment
(<2 years since tissue collection). Briefly, this assay is
a targeted sequencing assay that uses anchored mul-
tiplex polymerase chain reactions to prepare target-
enriched cDNA libraries from RNA to detect fusions
and other mutations in >50 genes linked to carcino-
mas and other solid tumours, known sarcoma and
haematological malignancy-associated fusions and
prominent BRAF and PDGFRA mutations by the use
of next-generation sequencing. This technology
allows the detection of not only known recurrent
fusions, but also previously unidentified fusions, so
long as one of the fusion partners is included in the
panel. Anchored multiplex polymerase chain reaction
creates target-enriched libraries by using a combina-
tion of unidirectional gene-specific primers and
universal adapters to enrich for both known and
unknown mutations. Adapters that contain both
molecular barcode adapters and sample indices per-
mit quantitative multiplex data analysis, read dedupli-
cation, and accurate mutation calling. Molecular
barcode adapters aid in error correction, sample iden-
tification, deduplication, and duplicate read binning
for confident mutation detection. Genes targeted in
this assay include: AKT3, ALK, ARHGAP26, AXL,
BRAF (fusion and V600E mutation), BRD3, BRD4,
EGFR (fusion and mutation), ERG, ESR1, ETV1,
ETV4, ETV5, ETV6, EWSR1, FGFR1, FGFR2, FGFR3,
FGR, INSR, MAML2, MAST1, MAST2, MET (fusion
and mutation), MSMB, MUSK, MYB, NOTCH1,
NOTCH2, NRG1, NTRK1, NTRK2, NTRK3, NUMBL,
NUTM1, PDGFRA (fusion and mutation), PDGFRB,
PIK3CA, PKN1, PPARG, PRKCA, PRKCB, RAF1,
RELA, RET, ROS1, RSPO2, RSPO3, TERT, TFE3,
TFE3, TFEB, THADA, and TMPRSS2.
Results
The age distribution of the 12 patients studied ranged
from 26 to 87 years (median 62.5 years); there were
five men and seven women. Three of the 12 patients
had recurrent or persistent tumour in more than one
transurethral resection. One had multiple recur-
rences, which were ultimately managed with
A B
C D
Figure 1. A, The histological appearance of a case of USP6-rearranged nodular fasciitis demonstrates fusiform cells with areas of myxoid
oedematous stroma. B, Break-apart fluorescence in-situ hybridisation (FISH) shows rearrangement of USP6, with separation of one pair of
green and red signals. C, Pseudosarcomatous myofibroblastic proliferation of the urinary bladder has a very similar morphological appear-
ance. D, However, break-apart FISH is negative for USP6 rearrangement.
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cystectomy. Three of 10 patients had a known his-
tory of previous instrumentation in the bladder, and
one had undergone prior uterine surgery. The histo-
logical findings were similar in all cases, irrespective
of age, site, and recurrence status, as described in the
criteria and Discussion. ALK immunohistochemical
staining was negative in all cases. FISH analysis (Fig-
ure 1C,D) for USP6 gave negative results in all 12
cases (0/12), including 10 large tumours [making up
multiple tissue cassettes of lesional tissue, (Figure 2)]
and two small lesions (entirely examined in one or
two tissue cassettes). FISH analysis for ROS1 and
ETV6 gave negative results in seven of the 12 cases
(0/7). The remaining cases lacked hybridisation sig-
nals even after repeated hybridisation. The next-gen-
eration sequencing revealed no identifiable gene
fusions from the studied panel of >50 genes in two
cases with adequate genetic material for evaluation,
which included ROS1 in one of the cases that failed
FISH (total 0/8 for ROS1).
Discussion
Pseudosarcomatous myofibroblastic proliferation is a
descriptive term that encompasses the mucosal
lesions postoperative spindle cell nodule, visceral
fasciitis, pseudosarcomatous fibromyxoid tumour,
pseudomalignant spindle cell proliferation, and
inflammatory pseudotumour.1 In general, the term
postoperative spindle cell nodule is principally used in
the setting of previous injury or biopsy, in contrast to
other terms used when the mass occurs idiopathi-
cally. These spindle-shaped cells show ultrastructural
features of myofibroblasts intermediate between a
fibroblast and smooth muscle cell.15,16 Although this
has been reported in multiple mucosal sites, the uri-
nary tract is among the most common locations. In
addition to these several names, it also remains a
subject of debate whether this entity is part of the
spectrum of inflammatory myofibroblastic tumour.2–4
Both of these entities have very similar morphology,
with, perhaps, the exception of a lesser inflammatory
component in pseudosarcomatous myofibroblastic
proliferation, and both have a myofibroblastic
immunohistochemical phenotype. Although inflam-
matory myofibroblastic tumour of soft tissue is classi-
fied as a neoplasm of intermediate malignancy, both
of these entities in the urinary tract are characteristi-
cally non-aggressive (without metastasis, although
persistence or recurrence, requiring multiple surg-
eries, can occur). In general, our practice is to reserve
the term inflammatory myofibroblastic tumour (in
the genitourinary tract) predominantly for tumours
A B
C D
Figure 2. A, Gross appearance of a partial cystectomy specimen from a case of pseudosarcomatous myofibroblastic proliferation of the uri-
nary bladder shows a solid, white mass in the wall of the urinary bladder. B, The same tumour shows nodular fasciitis-like histology. C,
Immunohistochemical staining for smooth muscle actin demonstrates diffuse, strong staining, consistent with a myofibroblastic pattern. D,
Keratin (broad-spectrum cocktail) immunohistochemical staining demonstrates substantial labelling, in contrast to classic soft tissue nodular
fasciitis.
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with ALK immunohistochemical positivity or ALK
rearrangement; however, even this is a subject of
debate, as some studies have found that cases with
positive ALK immunohistochemical staining do not
necessarily always harbour ALK rearrangement, mak-
ing this distinction imprecise.1,4,5,11
Histologically, pseudosarcomatous myofibroblastic
proliferations are composed of proliferations of spin-
dle-shaped cells with loose myxoid stroma or tight
fascicles. They have variable degrees of mitotic activ-
ity and inflammatory cell infiltrate. However, marked
pleomorphism, atypical mitosis and necrosis are
absent. Immunohistochemically, these typically stain
for muscle-specific actin, smooth muscle actin (Fig-
ure 2C), sometimes desmin, and often cytokeratin
(Figure 2D). Overall, these could be argued to resem-
ble soft tissue nodular fasciitis in both histology and
reactivity for smooth muscle actin; however, labelling
for keratin is typically a point of distinction that is
frequently present in bladder myofibroblastic tumours
but lacking in nodular fasciitis.17,18 Despite the fact
that nodular fasciitis has long been considered to be
an often self-limiting exuberant reactive lesion, clonal
rearrangement of the USP6 locus at 17p13 resulting
in MYH9–USP6 fusion has been recently identified,
suggesting that, rather than being a purely reactive
process, this may in fact represent a transient form of
neoplasia. It is of note that nodular fasciitis also shares
with pseudosarcomatous myofibroblastic proliferation
of the urinary tract an incomplete association with
preceding trauma. Therefore, in soft tissue tumour
pathology, evaluation for USP6 rearrangement may be
a potentially helpful technique to resolve challenging
diagnostic cases.19 Interestingly, rearrangement of the
USP6 locus is also shared by aneurysmal bone cyst,20
which is histologically quite different, although per-
haps less so if one considers the bland spindle-shaped
cell component of aneurysmal bone cyst to be the true
neoplastic cell population. Despite the histological,
immunophenotypic, and ultrastructural16,21,22 similar-
ities between pseudosarcomatous myofibroblastic
proliferation of the genitourinary tract and nodular
fasciitis, we found that these lesions lacked USP6 rear-
rangement (Figure 1D), which refutes our hypothesis
that this may be its visceral equivalent.
The staining for cytokeratin that is often present in
pseudosarcomatous myofibroblastic proliferation may
also raise consideration of sarcomatoid urothelial car-
cinoma; however, features than can be helpful in dis-
tinguishing these entities include reactivity for p63 or
GATA3 in sarcomatoid carcinoma, and a usual lack
of reactivity for desmin and a limited extent of label-
ling for smooth muscle actin in sarcomatoid
carcinoma.23 Although cytokeratin staining is often
present in pseudosarcomatous myofibroblastic prolif-
eration, staining for high molecular weight cytoker-
atin is characteristically absent, contrasting with
urothelial carcinoma.24
A limitation of this study is that the FISH and
sequencing testing employed were targeted only at
known gene fusions, and was therefore not designed
to entirely identify novel gene fusions. Further studies,
such as with RNA sequencing or other techniques,
may determine whether these pseudosarcomatous
myofibroblastic proliferations of the urinary tract rep-
resent a benign neoplasm, like nodular fasciitis, but
with a so far unknown gene fusion, or whether they
represent an exuberant reactive process, as nodular
fasciitis was originally postulated to be. On the basis of
our current data, this diagnosis remains principally
based on morphological and immunohistochemical
features, without a known confirmatory molecular fea-
ture. If these rearrangements ever occur in pseudosar-
comatous myofibroblastic proliferations of the urinary
tract, their rate is probably sufficiently low that testing
is not a robust diagnostic tool.
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